218 results on '"Díez-Campelo M"'
Search Results
2. Síndromes mielodisplásicos
3. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
4. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
5. P118 - Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
6. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
7. P075 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW CYTOKINES AND CHEMOKINES CONCENTRATIONS IN MYELODISPLASTIC NEOPLASMS
8. P074 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW MICROENVIRONMENT CHANGES IN MYELODYSPLASTIC NEOPLASMS AND ITS RELATIONSHIP WITH CLONAL HEMATOPOIESIS
9. P052 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
10. P041 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
11. O10 - CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES
12. Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients
13. P39 The Humanistic Burden of Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes on Patients and Caregivers: Qualitative Research Findings
14. Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data
15. P756: ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM (MDS/MPN) OVERLAP SYNDROMES. A SINGLE CENTER EXPERIENCE AND DISSECTION OF MUTATIONAL PROFILE
16. P788: FACTORS DRIVING TREATMENT DECISION IN PATIENTS WITH INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS): A RETROSPECTIVE ANALYSIS FROM THE GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS SPANISH MDS REGISTRY
17. Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia
18. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations
19. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus
20. P36 - Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS MAY ENHANCE RESIDUAL HEALTHY HAEMATOPOIESIS IN LOW-RISK MDS PATIENTS
21. P30 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: RELATION BETWEEN INMUNE CELL POPULATIONS AND MALIGNANT CLONE MUTATIONAL STATUS IN MYELODYSPLASTIC SYNDROMES
22. P31 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: PHENOTYPE AND GENOTYPE OF NATURAL KILLERS IN MYELODISPLASITIC SYNDROME
23. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
24. O20 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCORPORATION OF COHESIN MUTATIONAL DATA INTO CURRENT IPSS-R CLASSIFICATION REFINES THE PROGNOSTIC STRATIFICATION OF VERY LOW/LOW-RISK MYELODYSPLASTIC SYNDROMES
25. Topic: AS02-Epidemiology
26. Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche
27. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
28. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
29. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes
30. Diagnostic utility of bone marrow examination for the assessment of patients with fever of unknown origin: a 10-year single-centre experience
31. Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study
32. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD)
33. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
34. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation
35. MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS
36. S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
37. PF541 TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES
38. PF533 MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS
39. PF240 COMBINED INHIBITION OF SHP1 AND SHP2 WITH PHORBOL ESTERS AS A DIFFERENTIATION THERAPY AGAINST ACUTE MYELOID LEUKEMIA
40. TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES
41. 41 - Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation
42. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes
43. Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation
44. Mutational Status of Mesenchymal Stem Cell in Myelodysplastic Syndromes Patients
45. Mutational and Clonal Dynamics During Progression from MDS to SAML by Whole-Exome and Targeted-Deep Sequencing
46. Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence
47. What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools
48. DNA Repair Genes Transcriptome in Chronic Myelomonocytic Leukemia
49. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
50. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.